Filapixant (N = 23) | Placebo (N = 23) |
|---|
20 mg | 80 mg | 150 mg | 250 mg | (20 mg) | (80 mg) | (150 mg) | (250 mg) |
|---|
N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) |
|---|
1 (4.3%) | 3 (13.0%) | 10 (43.5%) | 13 (56.5%) | 2 (8.7%) | 2 (8.7%) | 4 (17.4%) | 3 (13.0%) |
- The table provides the number of patients reporting taste-related adverse events for each dose step where such an event was present, irrespective of the time of its onset. The number of patients reporting taste-related AEs might decrease from one dose step to the next when taste disorders disappear in a patient. Taste-related adverse events were ageusia, dysgeusia, hypogeusia, and taste disorder without further specification (MedDRA v22.0 preferred terms)
